We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.49B
AUM Growth
-$396M
Cap. Flow
-$222M
Cap. Flow %
-3.41%
Top 10 Hldgs %
43.16%
Holding
163
New
23
Increased
16
Reduced
43
Closed
16

Top Buys

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$643M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$97.4M
3
BLU
BELLUS Health Inc.
BLU
+$50.7M
4
ISO
IsoPlexis Corporation Common Stock
ISO
+$45.4M
5
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$33.3M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$79.2M
2
NVTA
Invitae Corporation
NVTA
+$50.6M
3
BEAM icon
Beam Therapeutics
BEAM
+$46.8M
4
DBVT
DBV Technologies
DBVT
+$37.7M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 84.55%
2 Financials 0.8%
3 Industrials 0.09%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$482M 7.42%
3,283,783
-103,962
-3% -$16.1M
LIAN
2
DELISTED
LianBio American Depositary Shares
LIAN
$347M 5.35%
+56,319,960
New +$643M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$307M 4.73%
26,559,443
– –
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$301M 4.63%
4,849,912
– –
IOVA icon
5
Iovance Biotherapeutics
IOVA
$2.04B
$193M 2.98%
10,127,941
-1,361,831
-12% -$30M
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$187M 2.89%
1,738,140
-218,800
-11% -$23.9M
MGTX icon
7
MeiraGTx Holdings
MGTX
$1.08B
$165M 2.54%
6,948,277
– –
CERE
8
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$165M 2.54%
5,086,727
– –
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.88B
$147M 2.26%
5,163,517
+1,200,000
+30% +$29.6M
RXDX
10
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$125M 1.93%
3,172,785
-141,247
-4% -$4.42M
VBIV
11
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$122M 1.89%
1,744,500
-90,249
-5% -$7.6M
BBIO icon
12
BridgeBio Pharma
BBIO
$16.6B
$119M 1.83%
7,128,755
-628,173
-8% -$26.6M
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$108M 1.67%
6,480,000
-991,798
-13% -$16.3M
RAPT
14
DELISTED
RAPT Therapeutics
RAPT
$108M 1.66%
365,946
+2,500
+0.7% +$668K
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$12B
$104M 1.61%
+1,180,000
New +$97.4M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$101M 1.56%
3,449,915
-957,484
-22% -$29.7M
CHRS icon
17
Coherus Oncology
CHRS
$222M
$86.3M 1.33%
5,407,798
+628,411
+13% +$11M
OM icon
18
Outset Medical
OM
$86.4M
$85.9M 1.32%
124,226
-8,483
-6% -$6.27M
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.21B
$75.3M 1.16%
2,411,447
+389,396
+19% +$11.6M
LABP
20
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$71.4M 1.1%
1,486,992
– –
CCCC icon
21
C4 Therapeutics
CCCC
$389M
$71.1M 1.1%
2,208,913
-49,653
-2% -$1.96M
APLS
22
DELISTED
Apellis Pharmaceuticals
APLS
$68.6M 1.06%
1,451,700
+836,700
+136% +$32.9M
BLU
23
DELISTED
BELLUS Health Inc.
BLU
$61.5M 0.95%
+7,645,234
New +$50.7M
ZYME icon
24
Zymeworks
ZYME
$1.63B
$60.3M 0.93%
3,679,845
– –
RLAY icon
25
Relay Therapeutics
RLAY
$3.96B
$59.7M 0.92%
1,943,097
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Perceptive Advisors held 163 positions worth $6.49B, down 5.7% from $6.88B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Perceptive Advisors withdrew a net $222M in Q4 2021, closing 16 positions and reducing 43 holdings. Its most notable exit was Atea Pharmaceuticals, an estimated $79.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 84% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in LianBio American Depositary Shares worth $347M.

  • Perceptive Advisors's largest Q4 2021 buy was LianBio American Depositary Shares: 56,319,960 shares worth $347M.
  • Perceptive Advisors added most to Apellis Pharmaceuticals in Q4 2021, an estimated $32.9M increase.
  • Perceptive Advisors's biggest Q4 2021 reduction was Invitae Corporation, cutting an estimated $50.6M.
  • Perceptive Advisors fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $79.2M.
  • Perceptive Advisors's ten largest holdings make up 43% of its $6.49B portfolio in Q4 2021.
  • Perceptive Advisors opened 23 new positions and closed 16 in Q4 2021.
  • Perceptive Advisors's portfolio value fell 5.7% quarter-over-quarter to $6.49B.

Based on Perceptive Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.